William Blair Issues Positive Estimate for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN - Free Report) - Analysts at William Blair lifted their Q1 2025 earnings per share estimates for Amgen in a report issued on Monday, April 14th. William Blair analyst M. Phipps now forecasts that the medical research company will earn $3.95 per share for the quarter, up from their previous forecast of $3.89. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen's FY2026 earnings at $19.47 EPS.

A number of other analysts also recently weighed in on the stock. Piper Sandler increased their price target on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Bank of America raised their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Amgen currently has an average rating of "Hold" and a consensus price target of $310.57.

Amgen Trading Up 1.3 %

Shares of Amgen stock traded up $3.58 during trading on Thursday, reaching $277.26. 590,972 shares of the company were exchanged, compared to its average volume of 2,781,194. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a market capitalization of $149.07 billion, a price-to-earnings ratio of 36.72, a P/E/G ratio of 2.63 and a beta of 0.59. The business has a 50-day moving average price of $302.62 and a 200-day moving average price of $293.55.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.

Institutional Investors Weigh In On Amgen

A number of institutional investors have recently made changes to their positions in AMGN. Centricity Wealth Management LLC bought a new position in Amgen during the fourth quarter worth about $25,000. Pinney & Scofield Inc. acquired a new position in Amgen during the 4th quarter worth approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $34,000. Finally, Atala Financial Inc acquired a new stake in Amgen during the 4th quarter worth approximately $34,000. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last 90 days. Company insiders own 0.69% of the company's stock.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.